Do GLP-1 Drugs Cause Hair Loss and 'Ozempic Face'?

Yes, hair loss is a recognised side effect of GLP-1 weight-loss medicines, and it usually passes. In the US prescribing information it affected about 3% of adults on Wegovy and 4–5% on Zepbound, against about 1% on placebo, mostly women, and both labels say it was associated with weight reduction.¹² It usually looks like telogen effluvium, the shedding that follows rapid weight loss, although a direct drug effect has not been ruled out.³⁴ "Ozempic face" is a media nickname for facial fat loss after large weight loss, from any cause.⁵

This page covers what the labels and studies show for semaglutide and tirzepatide, whether the hair comes back, when shedding needs a doctor, and what is known about facial change and loose skin. It gives no dosing information, recommends no products and is not medical advice.

How often hair loss happens on Wegovy and Zepbound

The most reliable figures come from the randomised, placebo-controlled trials summarised in each medicine's US label. The table lists every hair-loss figure in the current DailyMed labels, checked on 22 October 2026. The rates come from different trials, so don't compare them directly between drugs.

Two things stand out. Women were affected far more often than men. And the higher Wegovy dose, which produced more weight loss (18.8% versus 15.5% on average at 72 weeks in one trial), came with more hair loss.¹ That fits a weight-loss explanation, but dose and weight loss rise together, so the label cannot separate them. Zepbound's three doses, by contrast, gave similar rates (5%, 4% and 5%).²

Pooled data point the same way. A 2026 meta-analysis of nine interventional studies, seven of them randomised, covering 4,114 people on GLP-1 drugs, found hair loss about three times as often as on placebo, with an overall rate of 3.9%.⁸ A 2026 BMJ study of US health records compared about 12,000 adults with type 2 diabetes starting a GLP-1 drug with people starting two other classes of diabetes drug. GLP-1 drugs were linked to more non-scarring hair loss; the authors stressed that "the absolute risk is low", and the link weakened after a statistical check for hidden bias.⁹ Record studies like this show an association, not cause; see correlation versus causation.

Is it the drug or the weight loss?

Most hair loss on these medicines looks like telogen effluvium.¹⁰ After a physical shock such as illness, surgery or a crash diet, many follicles switch to their resting phase at once, and the hairs fall out weeks to months later.⁴ The American Academy of Dermatology lists losing 20 pounds or more among common triggers.¹¹

Several lines of evidence favour weight loss as the main cause. Both labels describe the hair loss as "associated with weight reduction".¹² Weight-loss surgery produces the same problem, more often: a 2025 meta-analysis of 41 studies with 7,044 patients found hair loss in 47% of people after bariatric surgery.¹² An earlier review found it was more common in younger women and in people with low zinc, folic acid or ferritin (stored iron), and less common with longer follow-up.¹³ A 2026 narrative review concluded that GLP-1 hair loss is "driven primarily by the magnitude and velocity of weight loss rather than drug toxicity", with women and people losing more than 10% of body weight most affected.¹⁰

But nobody has tested it directly. A 2026 review by European hair specialists named rapid weight loss as one potential mechanism, found no prospective controlled study designed to answer the question, and said "causality has not been established". Two of its authors work for Pierre Fabre, a hair-care maker, and others have consulted for companies including Eli Lilly.³ A 2026 meta-analysis of observational studies also linked GLP-1 drugs to pattern hair loss, not just shedding, and blamed nutrient shortfalls during weight loss; its studies were record studies, drug-safety report analyses and case series, which cannot prove cause.¹⁴

So weight loss is the leading explanation, and a direct effect on the follicle remains possible but unshown. Our guide to how GLP-1 drugs work covers their other side effects.

Will the hair grow back?

Usually, if it is telogen effluvium. MedlinePlus, from the US National Library of Medicine, says this kind of shedding often shows up weeks to months after the trigger, decreases over 6 to 8 months and is usually temporary, though it can become long-term.⁴ The American Academy of Dermatology says hair tends to regain its normal fullness within six to nine months, but shedding can continue while the stressor does.¹¹ On a weight-loss medicine, weight can keep falling for many months, so shedding may last longer than it would after a single event.

Two caveats. The observational link with pattern hair loss matters here, because hereditary hair loss tends to continue without treatment rather than recover.¹⁴¹¹ And we found no trial that followed regrowth after hair loss on these drugs, or that tested anything to prevent it. After bariatric surgery, hair loss became less common with longer follow-up.¹³

What to do if your hair is shedding

Don't stop the medicine on your own. The American Academy of Dermatology advises anyone who suspects a medicine is causing hair loss to talk to their doctor first, because stopping a treatment suddenly can have serious side effects.¹¹ If you are weighing it up, our guide to stopping semaglutide or tirzepatide explains what tends to happen to weight afterwards.

Get checked promptly if it isn't the usual diffuse shedding. MedlinePlus advises contacting a health professional for hair loss in an unusual pattern, rapid hair loss, pain or itching, a red or scaly scalp, bald spots in the beard or eyebrows, or hair loss with weight gain, muscle weakness, feeling cold or tiredness. It lists thyroid disease, anaemia and alopecia areata, which causes bald patches, among other causes.⁴ The NHS lists weight loss and iron deficiency among causes of temporary hair loss and says to see a GP if you are worried.¹⁵

Mention how you are eating. Crash diets short of protein are a recognised cause of shedding.⁴ After bariatric surgery, low ferritin, zinc and folic acid were linked to hair loss.¹³ If your appetite is very low, ask your doctor or a dietitian whether your diet or blood tests need checking. We don't recommend supplements.

Report it. In the US, report side effects to FDA MedWatch; elsewhere, use your national regulator.¹⁶

What "Ozempic face" actually is

"Ozempic face" is a nickname, not a diagnosis. It describes hollow cheeks and temples, looser skin and deeper folds after weight loss on a GLP-1 drug, and online searches for it have risen alongside searches for face fillers and plastic surgeons.¹⁷ A 2026 review of 46 reports in Aesthetic Surgery Journal noted that the term "can imply a drug-specific adverse effect, although similar changes occur after other forms of substantial weight loss". It concluded that the evidence favours weight-loss-related deflation layered on each person's anatomy and age; bariatric patients show the same deflation, especially older patients and those who lose more weight.⁵

Hard measurements are scarce. The only scan-based study we found, a retrospective one at a single US hospital, compared scans of 20 patients before and after starting a GLP-1 drug. Midface volume fell by a median of 9%, mostly from fat just under the skin, and more in those who lost more weight: about 7% per 10 kg lost.¹⁸ A 2025 systematic review found 23 articles on GLP-1 drugs in plastic surgery, and its authors acknowledged it was "limited by study biases".¹⁷

Two common questions have no answer yet: whether fast weight loss is worse for the face than the same loss more slowly⁵, and whether facial volume returns when weight stabilises or is regained, which we found no study of. The muscle side of the same problem is covered in losing muscle on GLP-1 drugs.

Will loose skin tighten?

Often not completely. The evidence comes almost entirely from bariatric surgery, not GLP-1 drugs. A scoping review found excess skin in more than 70% of adults after bariatric surgery, with women reporting more of it and more problems from it than men; findings for age and amount of weight lost were inconsistent.¹⁹ A 2023 study linked the amount of excess skin to peak weight before surgery and current BMI.²⁰ The skin itself changes: compared with 20 people with severe obesity, 20 people after massive weight loss had fewer thick, organised collagen fibres and more thin, loosely arranged ones.²¹

Body-contouring surgery, such as a tummy tuck, is the established way to remove excess skin. A review of 24 studies found most post-bariatric patients wanted it but only 18.5% had it, mainly because of cost; most who did reported better quality of life.²²

Creams, serums and peptides

There is no good evidence that they fix either problem. The 2026 Aesthetic Surgery Journal review called the evidence for aesthetic treatments of GLP-1 facial changes "limited and largely uncontrolled".⁵ Peptide skin creams have mostly been tested in small, short studies, often run by ingredient makers; see how far peptides get through the skin. No peptide serum has been tested for shedding on GLP-1 drugs. Peptides for hair growth explains what the hair studies show, and our GHK-Cu explainer covers the copper peptide most often promoted for both.

What about retatrutide?

People often assume retatrutide, Eli Lilly's experimental triple agonist, will cause more hair loss because it produced large average weight loss over 80 weeks in the phase 3 TRIUMPH-1 trial.²³ That is a reasonable guess, not a finding, and Zepbound's flat rates across doses are a reminder that more drug does not always mean more shedding.²

As of 22 October 2026, we found no published hair-loss rate. Lilly's TRIUMPH-1 safety table lists side effects seen in at least 10% of participants plus selected events of special interest; hair loss is not among them, though dysesthesia, an abnormal skin sensation such as burning, is (12.5% at the highest dose versus 0.9% on placebo).²⁴ We could not access the full journal article or its supplement, which may report a lower-frequency rate. The phase 2 results on ClinicalTrials.gov list non-serious side effects seen in at least 5% of any group, and alopecia is not among them.²⁵ A 2026 study that used AI tools to sort Reddit posts about non-trial retatrutide found that of 7,823 users describing any symptom, 50 (0.6%) mentioned hair loss and 61 (0.8%) loose skin; posts like these cannot show how common a side effect is, and what people injected is unknown.²⁶ See retatrutide side effects for the full trial picture and gray-market retatrutide for what testing of unapproved products has found.